An In Vivo Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Advanced prostate cancer is characterized by significant chromosomal instability and copy number alterations.
• Identifying functional drivers within these genomic aberrations is crucial for understanding cancer progression.

Purpose of the Study:

• To identify novel oncogenes driving prostate cancer progression using a functional genomics approach.
• To investigate the role of Pygopus family PHD finger 2 (PYGO2) in prostate cancer.

Main Methods:

• Integrated analysis of prostate cancer genomic and transcriptomic datasets.
• An in vivo gain-of-function tumorigenesis screen of 276 putative oncogenes.
• Functional analysis of PYGO2, including overexpression and depletion studies.
• Correlation analysis with clinical data (Gleason score, metastasis).

Main Results:

• PYGO2 was identified as a top hit in the functional screen, located in the 1q21.3 amplicon.
• PYGO2 overexpression enhanced primary tumor growth and lymph node invasion.
• PYGO2 depletion inhibited prostate cancer cell invasion and tumor progression in vivo.
• PYGO2 upregulation correlated with higher Gleason scores and metastasis in clinical samples.
• PYGO2 is essential for Wnt/β-catenin signaling-induced transcriptional activation.

Conclusions:

• PYGO2 acts as a driver oncogene in prostate cancer, particularly within the 1q21.3 amplicon.
• PYGO2 is a potential prognostic biomarker for prostate cancer progression and metastasis.
• PYGO2 represents a potential therapeutic target for metastatic prostate cancer.